HHTM

MONTPELLIER, FRANCE — Sensorion on Monday reported updated six-month efficacy data from Cohort 2 of its Phase 1/2 Audiogene trial evaluating SENS-501, while also providing a development update on its GJB2 gene therapy program, GJB2-GT (SENS-601). The company said the six-month follow-up data from Cohort 2 showed sustained early efficacy signals in two of three patients treated with the higher

How has cochlear implant care evolved—and are clinical practices keeping pace with today’s technology? Brian Taylor speaks with Dr. Terry Zwolan, Senior Director of Medical Affairs at Cochlear Americas, about the evolution of cochlear implants and the newly developed the Cochlear™ Care Consensus. Drawing on more than three decades of experience, Dr. Zwolan reflects on how cochlear implant technology—and the

STÄFA, SWITZERLAND — Sonova Holding AG on Monday presented a renewed long-term strategy aimed at expanding its market leadership in hearing care, with an ambition to reach CHF 6 billion (~$6.7B USD) in revenue by fiscal year 2030/31. The company also said it intends to divest its Consumer Hearing business in order to focus more fully on its core hearing

OKLAHOMA CITY, OK — When people cannot hear their own voices, their tongue movements become less precise during speech, according to new research from the University of Oklahoma. The findings provide direct evidence of how hearing contributes to speech production and may help inform therapies for individuals with hearing loss or those affected by conditions such as tongue cancer. The

Organizers of the International Congress of Hearing Care Professionals (EUHA 2026) have announced that The Netherlands will serve as the partner country for this year’s event, taking place October 14–16, 2026, in Hanover, Germany. The partner country concept includes a range of program elements and activities that will be featured throughout the three-day congress. Planned highlights include expert presentations from

UTRECHT, THE NETHERLANDS — Neuromod Devices, a medical technology company focused on tinnitus treatment technology, has partnered with HearConsult to make the Lenire tinnitus treatment device available in The Netherlands. Lenire® is a bimodal neuromodulation device that has been shown to provide clinically significant relief from tinnitus across multiple clinical trials and in real-world patient settings.1,2,5 Tinnitus, commonly described as ringing,

What if cochlear implant care didn’t always require a trip to the clinic? Host Shari Eberts speaks with Dr. Kensi Saia, Product Manager at MED-EL, about how new telehealth tools are changing the way cochlear implant recipients and clinicians connect. MED-EL’s Remote Care platform and HearCare app allow audiologists to monitor devices, review patient data, and even make programming adjustments

By Dr. Jennifer J. Gans Tinnitus is the perception of sound—often described as ringing, buzzing, or humming—without an external source. Millions of people notice tinnitus at some point in their lives, yet only a small percentage find it distressing. Why does the same sound feel irrelevant to some people but overwhelming to others? The answer lies not in the sound

Central Auditory Processing Disorder (CAPD) remains one of the more complex and often misunderstood areas in audiology. In this week’s episode of This Week in Hearing, host Bob Traynor is joined by Dr. Frank Musiek to discuss the upcoming third annual “Quest for the Best in CAPD and Neuroaudiology” Pathways Symposium, a virtual event taking place March 28. During the

GN Store Nord A/S announced that it has entered into a definitive agreement to sell its Hearing business to Amplifon S.p.A., a global hearing care retailer. The transaction values the Hearing business at DKK 17.0 billion (~$2.5 billion USD)1 on a cash-free and debt-free basis. The deal will be settled with DKK 12.6 billion (~$1.85 billion USD)2 in cash and